Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma

Table 3

The serum SALL4 levels in HCC and controls (pg/mL).

Variables	Median	IQR	𝑃
HCC	130.43	89.40–258.47	<0.001
Chronic hepatitis	53.19	44.96–67.12
Liver cirrhosis	48.20	42.77–69.22
Certain controls	48.58	40.99–71.29

HCC: hepatocellular carcinoma.